|
Aug 6
|
3 Asian Value Stocks Estimated To Be Up To 48.2% Below Intrinsic Value
|
|
Aug 6
|
Everest Medicines Announces Full Approval of NEFECON® in Taiwan
|
|
Aug 1
|
Everest Medicines Expands Strategic Investment in I-MAB
|
|
Aug 1
|
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
|
|
Jul 25
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
|
|
Jun 26
|
Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025
|
|
Jun 25
|
3 Global Stocks Estimated To Be Up To 47.7% Below Intrinsic Value
|
|
Jun 25
|
Asian Value Stocks: Uncovering 3 Companies That May Be Trading Below Fair Value Estimates
|
|
Jun 24
|
Asian Stocks That May Be Trading Below Estimated Value In June 2025
|
|
Jun 9
|
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
|
|
Jun 6
|
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
|
|
May 23
|
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
|
|
Apr 21
|
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
|